JP5581227B2 - 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤 - Google Patents

硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤 Download PDF

Info

Publication number
JP5581227B2
JP5581227B2 JP2010550813A JP2010550813A JP5581227B2 JP 5581227 B2 JP5581227 B2 JP 5581227B2 JP 2010550813 A JP2010550813 A JP 2010550813A JP 2010550813 A JP2010550813 A JP 2010550813A JP 5581227 B2 JP5581227 B2 JP 5581227B2
Authority
JP
Japan
Prior art keywords
suspension composition
suspension
volume
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010550813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513492A5 (https=
JP2011513492A (ja
Inventor
バグワティー ピー． カブラ，
ルーマ サルカー，
Original Assignee
アルコン リサーチ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルコン リサーチ， リミテッド filed Critical アルコン リサーチ， リミテッド
Publication of JP2011513492A publication Critical patent/JP2011513492A/ja
Publication of JP2011513492A5 publication Critical patent/JP2011513492A5/ja
Application granted granted Critical
Publication of JP5581227B2 publication Critical patent/JP5581227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2010550813A 2008-03-11 2009-03-10 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤 Active JP5581227B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (3)

Publication Number Publication Date
JP2011513492A JP2011513492A (ja) 2011-04-28
JP2011513492A5 JP2011513492A5 (https=) 2012-03-22
JP5581227B2 true JP5581227B2 (ja) 2014-08-27

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550813A Active JP5581227B2 (ja) 2008-03-11 2009-03-10 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤

Country Status (21)

Country Link
US (3) US8128960B2 (https=)
EP (1) EP2262506B1 (https=)
JP (1) JP5581227B2 (https=)
KR (1) KR101555293B1 (https=)
CN (1) CN101959519B (https=)
AR (1) AR070824A1 (https=)
AU (1) AU2009223649B2 (https=)
BR (1) BRPI0909630B8 (https=)
CA (1) CA2717605C (https=)
CL (1) CL2009000573A1 (https=)
DK (1) DK2262506T3 (https=)
ES (1) ES2471122T3 (https=)
MX (1) MX2010009974A (https=)
PL (1) PL2262506T3 (https=)
PT (1) PT2262506E (https=)
RU (1) RU2481842C2 (https=)
SI (1) SI2262506T1 (https=)
TW (1) TWI468165B (https=)
UY (1) UY31699A1 (https=)
WO (1) WO2009114521A1 (https=)
ZA (1) ZA201005839B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
AU2009330517A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
JP5996544B2 (ja) 2010-10-15 2016-09-21 クリアサイド・バイオメディカル・インコーポレーテッドＣｌｅａｒｓｉｄｅ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 眼球アクセス用装置
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
EP3157598A4 (en) 2014-06-20 2018-05-16 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
AU2019207515B2 (en) * 2018-01-10 2024-11-14 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
CA3136814A1 (en) * 2019-04-16 2020-10-22 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法
CN115969784B (zh) * 2022-12-26 2025-10-21 昆明积大制药股份有限公司 曲安奈德注射液的制备方法
WO2025114562A1 (en) * 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Intravitreal spironolactone suspension

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
WO1996020712A1 (en) 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
CA2336703A1 (en) 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
WO2002015878A1 (fr) * 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
HRP20040102A2 (en) * 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2004073607A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Use of steroids to treat ocular disorders
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070225727A1 (en) 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
US8246949B2 (en) 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
AU2005306309A1 (en) 2004-11-17 2006-05-26 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Steroid formulation and methods of treatment using same
EP1867334A4 (en) 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
JP5581227B2 (ja) * 2008-03-11 2014-08-27 アルコン リサーチ， リミテッド 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤

Also Published As

Publication number Publication date
TWI468165B (zh) 2015-01-11
MX2010009974A (es) 2010-09-30
US8128960B2 (en) 2012-03-06
US20120116216A1 (en) 2012-05-10
EP2262506B1 (en) 2014-05-07
CL2009000573A1 (es) 2010-01-04
ES2471122T3 (es) 2014-06-25
TW200940071A (en) 2009-10-01
RU2481842C2 (ru) 2013-05-20
CA2717605C (en) 2012-05-15
KR20100127267A (ko) 2010-12-03
US20120115829A1 (en) 2012-05-10
SI2262506T1 (sl) 2014-07-31
CN101959519B (zh) 2013-03-20
BRPI0909630B1 (pt) 2019-03-26
JP2011513492A (ja) 2011-04-28
AR070824A1 (es) 2010-05-05
CN101959519A (zh) 2011-01-26
DK2262506T3 (da) 2014-06-10
BRPI0909630A2 (pt) 2015-09-22
EP2262506A1 (en) 2010-12-22
RU2010141542A (ru) 2012-04-20
AU2009223649A1 (en) 2009-09-17
KR101555293B1 (ko) 2015-10-06
US8211880B2 (en) 2012-07-03
HK1146464A1 (en) 2011-06-10
ZA201005839B (en) 2011-10-26
AU2009223649B2 (en) 2013-08-29
UY31699A1 (es) 2009-05-29
CA2717605A1 (en) 2009-09-17
BRPI0909630B8 (pt) 2021-05-25
WO2009114521A1 (en) 2009-09-17
US20090233890A1 (en) 2009-09-17
PL2262506T3 (pl) 2014-09-30
PT2262506E (pt) 2014-06-24

Similar Documents

Publication Publication Date Title
JP5581227B2 (ja) 硝子体内注射のための低粘度、高凝集トリアムシノロンアセトニド懸濁剤
US12016867B2 (en) Methods of treating inflammation and/or pain
KR102498075B1 (ko) 주사용 제제
JP2007506678A (ja) 注入のためのトリアムシノロンアセトアニドおよび酢酸アネコルタブの処方物
CN104220047A (zh) 含有生物治疗剂和胍或胍衍生物的水性药物组合物以及包含所述组合物的注射剂
HK1146464B (en) Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140714

R150 Certificate of patent or registration of utility model

Ref document number: 5581227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250